Skip to main content

Table 1 Biological and activity data of VEGFRi and EGFRi. Biological effect data were compiled from the information provided by the web site (accessed in November 2019). The “major skin effect” presented here is the most frequent cutaneous adverse reaction reported by the FDA Adverse Event Reporting System. NSCLC: non-small cell lung cancer. Drug KD and the determination of plasma concentration after a single dose administration in human are reported here from literature. Data from Klaeger et al. 2017 were used to compare drug KD for EGFRi. Unbound plasma drug fraction was determined as a concentration at nanomolar scale in the literature

From: EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function